Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,
It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.
Clopidogrel was granted FDA approval on 17 November 1997.
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT00263211
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Optimum Platelet Inhibition After Coronary Bypass Surgery
- Conditions
- Ischemic Heart Disease
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Papworth Hospital NHS Foundation Trust
- Registration Number
- NCT00262275
- Locations
- 🇬🇧
Papworth Hospital, Cambridge, United Kingdom
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
- Conditions
- Atrial FibrillationVascular Risk
- Interventions
- Drug: placebo
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2015-06-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 7554
- Registration Number
- NCT00249873
- Locations
- 🇧🇪
Sanofi-aventis Administrative Office, Diegem, Belgium
🇬🇧Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
🇦🇹Sanofi-Aventis, Wien, Austria
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)
- Conditions
- Atrial FibrillationVascular Risk
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2009-10-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 6706
- Registration Number
- NCT00243178
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Trial of Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial)
- Conditions
- Atherosclerosis
- Interventions
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Ottawa Heart Institute Research Corporation
- Target Recruit Count
- 113
- Registration Number
- NCT00228423
- Locations
- 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Impact of Medical and Surgical Therapy on Functional Mitral Regurgitation
- Conditions
- Heart DiseasesCardiovascular DiseasesCoronary Disease
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 250
- Registration Number
- NCT00224809
- Locations
- 🇺🇸
Baylor Research Institute, Dallas, Texas, United States
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.
- Conditions
- Coronary Heart DiseaseAngina PectorisAtherosclerosis
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-03-23
- Lead Sponsor
- Ullevaal University Hospital
- Target Recruit Count
- 1001
- Registration Number
- NCT00222261
- Locations
- 🇳🇴
Ullevaal University Hospital, Oslo, Norway
Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction
- Conditions
- Acute Myocardial Infarction
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2006-05-05
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 46000
- Registration Number
- NCT00222573
- Locations
- 🇨🇳
Institute of Cadiovascular diseases, Fuwai hospital, Chinese academy of medical sciences, Beijing, China
🇬🇧Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford, United Kingdom
The Effects of Physical Training, ASA (Aspirin), and Clopidogrel on the Walking Capacity of Patients With Stage II Peripheral Arterial Disease (PAD)
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-10-06
- Lead Sponsor
- Arteriogenesis Competence Network
- Target Recruit Count
- 250
- Registration Number
- NCT00189618
- Locations
- 🇨🇭
University Hospital Basel Dpt. Angiology, Basel, Switzerland
🇨🇭Ospedale San Giovanni, Bellinzona, Switzerland
🇨🇭Kantonsspital Bruderholz, Bruderholz, Switzerland
CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease
- Conditions
- Arterial Occlusive Diseases
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1460
- Registration Number
- NCT00174759
- Locations
- 🇬🇧
Sanofi-Aventis, Guildford, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.